Cision PR Newswire

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk...

China Liberal Education Holdings Limited Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

BEIJING, Jan. 13, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (NASDAQ: CLEU), a China-based company that provides technological consulting services...

Yiwu Brands Unite for Overseas Expansion with Grand Opening of Yiwu Selection Store

YIWU, China, Jan. 13, 2025 /PRNewswire/ -- Yiwu, the world's preeminent hub for small commodities, hosts an extensive trading network connecting the globe with...